NCT04966663View on ClinicalTrials.gov

Using ctDNA to Determine Therapies for Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 28, 2022

Primary Completion Date

August 1, 2025

Study Completion Date

December 1, 2026

Conditions
Non Small Cell Lung CancerComplete Surgical ResectionCirculating Tumor DNA
Interventions
DRUG

Nivolumab

Antineoplastic agent

DRUG

Pemetrexed

Antineoplastic agent

DRUG

Gemcitabine

Antineoplastic agent

DRUG

Cisplatin

Antineoplastic agent

DRUG

Carboplatin

Antineoplastic agent

PROCEDURE

ctDNA blood test

Blood will be collected for ctDNA testing

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University Health Network, Toronto

OTHER

NCT04966663 - Using ctDNA to Determine Therapies for Lung Cancer | Biotech Hunter | Biotech Hunter